Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA ME-TRAP
- Development stage
- Phase 2
- Lead developer
- University of Oxford
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
MVA ME-TRAP is a candidate malaria vaccine based on the Modified Vaccinia Virus Ankara (MVA) viral vector, engineered to express the multi-epitope thrombospondin-related adhesion protein (ME-TRAP) antigen from *Plasmodium falciparum*. The ME component consists of a string of 20 CD8+ T cell epitopes from six pre-erythrocytic antigens, fused to the TRAP protein, aiming to broaden and enhance immune responses against malaria. MVA ME-TRAP is typically used in heterologous prime–boost regimens with ChAd63 ME-TRAP (chimpanzee adenovirus vector), where it serves as the boost following priming with ChAd63. The vaccine induces both T-cell and antibody responses targeting liver-stage malaria parasites but has shown only moderate efficacy in field trials among children in highly endemic regions. It was developed primarily by researchers at the University of Oxford[3][5][8].
- Other names
- Modified Vaccinia Ankara multiple epitope thrombospondin-related adhesion proteinMVA-METRAP vaccine
02
Targets
TRAP (Thrombospondin-related anonymous protein)
Beyond the preview
Go deeper on MVA ME-TRAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA ME-TRAP.